Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
solid tumor
Biotech
Roche axes 4 Chugai solid tumor assets in early-phase clear-out
Roche's CEO framed the actions as a continuation of the company's work to ensure candidates clear “the bar” before advancing.
Nick Paul Taylor
Oct 23, 2025 4:53am
Takeda strikes Innovent pact worth up to $11.4B
Oct 22, 2025 9:15am
Tubulis touts $361M series C as next-gen ADC data drop nears
Oct 15, 2025 5:01am
CatalYm C-suite shake-up sees 4 new faces, 3 departures
Sep 15, 2025 10:53am
PMV plots ovarian cancer filing after seeing midphase data
Sep 10, 2025 9:40am
VantAI plays matchmaker for Halda's RIPTACs in $1B deal
Aug 19, 2025 8:00am